Methods of detecting glycated proteins

• US 5,110,745 A
• Filed: 06/01/1989
• Issued: 05/05/1992
• Est. Priority Date: 06/01/1989
• Status: Expired due to Fees

• Current Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Original Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: Kricka, Larry J., Wilding, Peter
• Primary Examiner(s): Hill, Jr., Robert J.
• Application Number:
  US07/359,953
• Time in Patent Office: 1,069 Days
• Field of Search: 436/67, 436/87, 436/88, 436/164, 436/175, 436/178, 436/501, 436/518, 436/815
• US Class Current: 436/87
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6842 Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
• CPC Class Codes: G01N 33/723 Glycosylated haemoglobin
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10T 436/255 including use of a solid sorbent, semipermeable membrane, or liquid extraction

Abstract

The invention discloses novel methods of detecting glycated proteins in test samples of blood and methods of detecting chronic hyperglycemia. The test sample is contacted with a binder composition under conditions which allow binding of glycated protein in the test sample to at least a portion of the binder composition. The test sample is then exposed to a glycated compound affixed to a solid support under conditions which allow raction of unbound binder composition from the previous step to at least a portion of the glycated compound on the solid support. The glycated compound affixed to a solid support from the previous step which did not react with the unbound binder composition is then reacted with a detecting agent and the detecting agent is detected.

Claims

1. A method of detecting glycated protein in a body fluid suspected of containing said glycated protein, comprising the steps of:

a) contacting a test sample of said body fluid with an excess of a binder composition under conditions which allow binding of glycated protein in said test sample to a portion of said binder composition thereby leaving a portion of said binder composition unbound with glycated protein;

b) exposing the unbound portion of said binder composition from step a to an excess of glycated compound affixed to a solid support under conditions which allow reaction of said unbound portion of said binder composition to a portion of said glycated compound affixed to a solid support thereby leaving a portion of said glycated compound affixed to a solid support unreacted with said unbound portion of said binder composition;

c) reacting the unreacted portion of said glycated compound affixed to a solid support from step b with a detecting agent; and

d) detecting said detecting agent.

2. The method of claim 1 wherein the binding of step (a), the reaction of step (b), and the reaction step of (c) are each substantially quantitative.

3. The method of claim 1 wherein said glycated protein is glycated-albumin.

4. The method of claim 1 wherein said glycated protein is glycated-hemoglobin.

5. The method of claim 1 wherein said body fluid is whole blood.

6. The method of claim 1 wherein said body fluid is plasma.

7. The method of claim 1 wherein said binder composition is ##STR2## wherein R is hydroxyl, phenyl or substituted phenyl.

8. The method of claim 7 wherein said binder composition is meta-aminophenyl boronic acid.

9. The method of claim 7 wherein said binder composition is boric acid.

10. The method of claim 1 wherein said glycated compound affixed to a solid support is a glycated protein.

11. The method of claim 10 wherein said glycated protein affixed to a solid support is glycated albumin.

12. The method of claim 10 wherein said glycated protein affixed to a solid support is glycated polylysine.

13. The method of claim 1 wherein said detecting agent is a tetrazolium derivative or salt.

14. The method of claim 13 wherein said detecting agent is nitro blue tetrazolium.

15. The method of claim 13 wherein said detecting agent is 3-(4,5-dimethylthiazol-2-yl)-2,5-phenyltetrazolium bromide.

16. The method of claim 13 wherein said detecting agent is 5-phenyltetrazolium bromide.

17. The method of claim 1 wherein said detecting step is performed by visual inspection of said detecting agent.

18. The method of claim 1 wherein said body fluid is serum.

19. A method of detecting chronic hyperglycemia in mammals, comprising

a) contacting a test sample of a body fluid from a mammal suspected of containing glycated protein with an excess of a binder composition under conditions which allow binding of glycated protein in said test sample to a portion of said binder composition thereby leaving a portion of said binder composition unbound with glycated protein;

b) exposing the unbound portion of said binder composition from step a to an excess of glycated compound affixed to a solid support under conditions which allow reaction of said unbound portion of said binder composition to a portion of said glycated compound affixed to a solid support thereby leaving a portion of said glycated compound affixed to a solid support unreacted with said unbound portion of said binder composition;

c) reacting the unreacted portion of said glycated compound affixed to a solid support from step b with a detecting agent; and

d) detecting said detecting agent

whereby the presence of detecting agent indicates the presence of glycated protein in said test sample and the presence in said mammal of chronic hyperglycemia.

20. The method of claim 19 wherein said mammal is a human.

21. The method of claim 19 wherein said body fluid is whole blood.

22. The method of claim 19 wherein said body fluid is plasma.

23. The method of claim 19 wherein said body fluid is serum.

24. The method of claim 19 wherein said binder composition is ##STR3## wherein R is hydroxyl, phenyl or substituted phenyl.

25. The method of claim 24 wherein said binder composition is meta-aminophenyl boronic acid.

26. The method of claim 24 wherein said binder composition is boric acid.

27. The method of claim 19 wherein said glycated compound affixed to a solid support is a glycated protein.

28. The method of claim 27 wherein said glycated protein affixed to a solid support is glycated albumin.

29. The method of claim 27 wherein said glycated protein affixed to a solid support is glycated polylysine.

30. The method of claim 19 wherein said detecting agent is a tetrazolium derivative or salt.

31. The method of claim 30 wherein said detecting agent is nitro blue tetrazolium.

32. The method of claim 30 wherein said detecting agent is 3-(4,5-dimethylthiazol-2-yl)-2,5-phenyltetrazolium bromide.

33. The method of claim 30 wherein said detecting agent is 5-phenyltetrazolium bromide.